# A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

> clinical trial · VERIFIED · 2026-07-16

Status: RECRUITING · Sponsor: Amgen · Condition: Small-cell Lung Cancer

- Company: Amgen
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07005128

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.